Opna Bio develops
drugs targeting the
Hallmarks of Cancer

OPN-6602

Dual Inhibitor
of EP300 and CBP

Nonmutational epigenetic
reprogramming

OPN-FMRP

FMRP
Inhibitor

Avoiding immune
destruction

OUR PIPELINE

In addition to its discovery-stage FMRP program, Opna Bio is targeting master regulators to advance the treatment of cancer. These include OPN-6602, a best-in-class EP300/CBP inhibitor, currently in preclinical development and expected to enter the clinic in 2024.

EXPLORE
Hanahan et al, November 2022

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

Upregulation of the neuronal fragile-X mental retardation protein in cancer cells suppresses proinflammatory signals to circumvent tumor immunity

Read More

LATEST NEWS

11 /2022

Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversified Pipeline of Clinical and Preclinical Programs

Gideon Bollag, PhD, Named CEO and Board Director.

Read More News